Department of Experimental and Clinical Medicine, "Politecnica delle Marche" University, Ancona, Italy.
IRCCS Fondazione Don Gnocchi, Milan, Italy.
Eur J Phys Rehabil Med. 2021 Oct;57(5):850-857. doi: 10.23736/S1973-9087.21.07301-9.
This paper updates and summarizes the current evidence informing rehabilitation of patients with COVID-19 and/or describing the consequences of the disease and its treatment.
Studies published from May 1 to June 30, 2021 were selected, excluding descriptive studies and expert opinions. Papers were categorized according to study design, research question, COVID-19 phase, limitations of functioning of rehabilitation interest, and type of rehabilitation service involved. From this edition, we improved the quality assessment using the Joanna Briggs Institute checklists for observational studies and the Cochrane Risk of Bias Tool for randomized-controlled clinical trials (RCTs).
Twenty-five, out of 3699 papers, were included. They were three RCTs, 13 cross-sectional studies and nine cohort studies. Twenty studies reported data on symptom prevalence (N.=13) or disease natural history (N.=7); and five studies reported intervention effectiveness at the individual level. All study participants were COVID survivors and 48% of studies collected information on participants 6 months or longer after COVID-19 onset. The most frequent risks of bias for RCTs concerned weaknesses in allocation concealment, blinding of therapists, and lack of intention-to-treat analysis. Most analytical studies failed to identify or deal with confounders, describe or deal with dropouts or eventually perform an appropriate statistical analysis.
Most studies in this updated review targeted the prevalence of limitations of functioning of rehabilitation interest in COVID-19 survivors. This is similar to past review findings; however, data in the new studies was collected at longer follow-up periods (up to one year after symptom onset) and in larger samples of participants. More RCTs and analytical observational studies are available, but the methodological quality of recently published studies is low. There is a need for good quality intervention efficacy and effectiveness studies to complement the rapidly expanding evidence from observational studies.
本文更新并总结了目前关于 COVID-19 患者康复的证据,以及描述疾病及其治疗的后果。
选择 2021 年 5 月 1 日至 6 月 30 日发表的研究,排除描述性研究和专家意见。根据研究设计、研究问题、COVID-19 阶段、康复兴趣的功能受限、以及涉及的康复服务类型对论文进行分类。从这一版本开始,我们使用 Joanna Briggs 研究所观察性研究检查表和 Cochrane 随机对照临床试验(RCT)偏倚风险工具改进了质量评估。
从 3699 篇论文中筛选出 25 篇,包括 3 项 RCT、13 项横断面研究和 9 项队列研究。20 项研究报告了症状流行率(N=13)或疾病自然史(N=7)的数据;5 项研究报告了个体层面的干预效果。所有研究参与者均为 COVID 幸存者,48%的研究在 COVID-19 发病后 6 个月或更长时间收集参与者的信息。RCT 最常见的偏倚风险包括分配隐藏、治疗师盲法和缺乏意向治疗分析的弱点。大多数分析性研究未能识别或处理混杂因素、描述或处理失访,或最终进行适当的统计分析。
本综述更新后的大多数研究针对 COVID-19 幸存者康复功能受限的流行率。这与过去的综述结果相似;然而,新研究中的数据是在更长的随访期(症状出现后长达一年)和更大的参与者样本中收集的。有更多的 RCT 和分析性观察性研究,但最近发表的研究的方法学质量较低。需要高质量的干预效果和有效性研究来补充快速扩展的观察性研究证据。